Literature DB >> 19365835

Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.

Lesley A Anderson1, Shahinaz Gadalla, Lindsay M Morton, Ola Landgren, Ruth Pfeiffer, Joan L Warren, Sonja I Berndt, Winnie Ricker, Ruth Parsons, Eric A Engels.   

Abstract

Some autoimmune conditions are associated with increased risk of lymphoid malignancies, but information on specific malignancy subtypes is limited. From the U.S. Surveillance Epidemiology and End Results-Medicare database, we selected 44,350 lymphoid malignancy cases (> or =67 years) and 122,531 population-based controls. Logistic regression was used to derive odds ratios (ORs) comparing the prevalence of autoimmune conditions in cases and controls, by lymphoid malignancy subtype, adjusted for gender, age at malignancy/selection, year of malignancy/selection, race and number of physician claims. The strongest associations observed by non-Hodgkin lymphoma (NHL) subtypes were diffuse large B-cell lymphoma with rheumatoid arthritis (OR 1.4, 95%CI 1.2-1.5) and Sjögren syndrome (2.0, 1.5-2.8); T-cell lymphoma with hemolytic anemia (9.7, 4.3-22), psoriasis (3.1, 2.5-4.0), discoid lupus erythematosus (4.4, 2.3-8.4) and celiac disease (5.0, 2.4-14.); and marginal zone lymphoma with Sjögren syndrome (6.6, 4.6-9.5), systemic lupus erythematosus (2.8, 1.7-4.7) and hemolytic anemia (7.4, 3.1-18). Hodgkin lymphoma was associated with systemic lupus erythematosus (3.5, 1.9-6.7). Multiple myeloma was associated only with pernicious anemia (1.5, 1.3-1.7). Several autoimmune conditions were associated with increased risk of lymphoid neoplasms, especially NHLs of diffuse large B-cell, marginal zone and T-cell subtypes. These results support a mechanism whereby chronic antigenic stimulation leads to lymphoid malignancy. Published 2009 UICC.

Entities:  

Mesh:

Year:  2009        PMID: 19365835      PMCID: PMC2692814          DOI: 10.1002/ijc.24287

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  47 in total

1.  Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia.

Authors:  S Sallah; J Y Wan; L R Hanrahan
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

2.  Two cases of sarcoidosis-lymphoma syndrome.

Authors:  Nada Suvajdzic; Branislava Milenkovic; Maja Perunicic; Jelena Stojsic; Snezana Jankovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.

Authors:  F R Mauro; R Foa; R Cerretti; D Giannarelli; S Coluzzi; F Mandelli; G Girelli
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

4.  Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden.

Authors:  P Boffetta; G Gridley; B Lindelöf
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

5.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

Review 6.  Post-transplant lymphoproliferative disorders.

Authors:  Stephen Gottschalk; Cliona M Rooney; Helen E Heslop
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

7.  Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.

Authors:  B Maes; A Anastasopoulou; J C Kluin-Nelemans; I Teodorovic; R Achten; A Carbone; C De Wolf-Peeters
Journal:  Ann Oncol       Date:  2001-06       Impact factor: 32.976

8.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

9.  Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma.

Authors:  Lene Mellemkjaer; Ruth M Pfeiffer; Eric A Engels; Gloria Gridley; William Wheeler; Kari Hemminki; Jørgen H Olsen; Lene Dreyer; Martha S Linet; Lynn R Goldin; Ola Landgren
Journal:  Arthritis Rheum       Date:  2008-03

10.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.

Authors:  Karin Ekström Smedby; Claire M Vajdic; Michael Falster; Eric A Engels; Otoniel Martínez-Maza; Jennifer Turner; Henrik Hjalgrim; Paolo Vineis; Adele Seniori Costantini; Paige M Bracci; Elizabeth A Holly; Eleanor Willett; John J Spinelli; Carlo La Vecchia; Tongzhang Zheng; Nikolaus Becker; Silvia De Sanjosé; Brian C-H Chiu; Luigino Dal Maso; Pierluigi Cocco; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Scott Davis; Richard Severson; James R Cerhan; Elizabeth C Breen; Brenda Birmann; Andrew E Grulich; Wendy Cozen
Journal:  Blood       Date:  2008-02-08       Impact factor: 22.113

View more
  80 in total

Review 1.  Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.

Authors:  Catarina Dias; David A Isenberg
Journal:  Nat Rev Rheumatol       Date:  2011-06       Impact factor: 20.543

2.  Running in the family: MALT lymphoma and autoimmune disease in mother and daughter.

Authors:  Barbara Kiesewetter; Marlene Troch; Leonhard Müllauer; Markus Raderer
Journal:  World J Gastrointest Oncol       Date:  2012-02-15

3.  Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults.

Authors:  Cindy M Chang; Joan L Warren; Eric A Engels
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

Review 4.  Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature.

Authors:  Joe Puthenparambil; Klaus Lechner; Gabriela Kornek
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

Review 5.  Advances in diagnosis and management of celiac disease.

Authors:  Ciarán P Kelly; Julio C Bai; Edwin Liu; Daniel A Leffler
Journal:  Gastroenterology       Date:  2015-02-03       Impact factor: 22.682

6.  Association of the four common polymorphisms in interleukin-10 (rs1800890, rs1800896, rs1800871, and rs1800872) with non-Hodgkin's lymphoma risk: a meta-analysis.

Authors:  Zhi-Ming Dai; Ai-Li He; Wang-Gang Zhang; Jie Liu; Xing-Mei Cao; Yin-Xia Chen; Xiao-Rong Ma; Wan-Hong Zhao; Zhi-Jun Dai
Journal:  Int J Clin Exp Med       Date:  2014-12-15

7.  Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases.

Authors:  Nada Suvajdzic; Predrag Djurdjevic; Milena Todorovic; Maja Perunicic; Roksanda Stojanović; Aleksandra Novkovic; Biljana Mihaljevic
Journal:  Med Oncol       Date:  2011-07-14       Impact factor: 3.064

8.  Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: a Children's Oncology Group study.

Authors:  Amy M Linabery; Erik B Erhardt; Rachel K Fonstad; Richard F Ambinder; Greta R Bunin; Julie A Ross; Logan G Spector; Seymour Grufferman
Journal:  Int J Cancer       Date:  2014-03-18       Impact factor: 7.396

9.  Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report.

Authors:  Amy M Linabery; Wenchao Li; Michelle A Roesler; Logan G Spector; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Julie A Ross
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-10       Impact factor: 4.254

10.  Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").

Authors:  Eric A Engels; Ruth Parsons; Caroline Besson; Lindsay M Morton; Lindsey Enewold; Winnie Ricker; Elizabeth L Yanik; Hannah Arem; April A Austin; Ruth M Pfeiffer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-26       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.